Immorality ruling India; no one, including me, can discuss morality: HDK

Bengaluru, Feb 7: Karnataka's Directorate of Health and Family Welfare Services on Thursday issued guidelines for testing, isolation, hospital admission and discharge in view of the outbreak of Novel Coronavirus (nCoV) in Wuhan city of China, a virus that has infected nearly 20,000 globally and has killed more than 500 in China.

According to the guidelines, the sample of any passenger, whether symptomatic or asymptomatic, with a history of travel to or residence in Wuhan city of China in the last 14 days, has to be collected and tested.

And the sample of any health personnel, who develops symptoms of the virus after being associated with the infected persons, has to be collected.

The circular further says that the clinical sample of any suspect/probable case of nCoV will be sent to the laboratory confirmation and the case will be kept in isolation. If tested positive, the treatment has to be provided as per the existing guidelines.

The virus originated from Wuhan, a Chinese city, in December and has since then spread to various parts around the world.

China has imposed quarantine and travel restrictions, affecting the movement of 56 million people in more than a dozen cities, amid fears that the transmission rate will accelerate.

Bengaluru, Jun 7: Fatalities due to coronavirus reached 61 in Karnataka with two more deaths, while 239 more tested positive for the viral infection, pushing the tally in the state to 5,452, the health department said on Sunday.

The total COVID-19 cases in the state include 2,132 discharges, 3,257 active cases and 61 deaths. A 61-year-old woman suffering from hypothyroidism and was diagnosed with Severe Acute Respiratory Illness (SARI) died on Saturday whereas a 57-year-old man having filariasis and chronic nyeloid leukemia died on Sunday in Bengaluru.

Most of those who contributed for Sunday's new cases were interstate passengers. 183 passengers, most of whom returned from Maharashtra were tested positive for the virus, the health bulletin said.

According to the health department, 39 coronavirus positive cases were reported in Kalaburagi and Yadagiri, 38 in Belagavi, 23 in Bengaluru urban, 17 each in Dakshina Kannada and Davangere, 13 in Udupi, 12 in Shivamogga, nine in Vijayapura, seven in Bidar, six in Ballari, five each in Bengaluru Rural and Hassan, three in Dharwad, two each in Gadag and Uttara Kannada and one each in Mandya and Raichur.

India today reported the highest single-day spike of 9,971 new Covid-19 cases and 287 deaths in the last 24 hours, taking the total number of cases in the country to 2,46,628

.

The United States of America has bought almost the entire world's supply of remdesivir, one of just two drugs proven to treat COVID-19. 

“President Trump has struck an amazing deal to ensure Americans have access to the first authorised therapeutic for Covid-19,” said the US health and human services secretary, Alex Azar. 

“To the extent possible, we want to ensure that any American patient who needs remdesivir can get it. The Trump administration is doing everything in our power to learn more about life-saving therapeutics for Covid-19 and secure access to these options for the American people.”

The announcement implies that no other country in the world will be able to buy remdesivir for next three months at least.

The anti-viral drug patented by the US-based Gilead biotech firm is the only one approved by the European Medicines Agency (EMA) to treat patients with the novel coronavirus.

The Trump administration has already shown that it is prepared to outbid and outmanoeuvre all other countries to secure the medical supplies it needs for the US.

“They’ve got access to most of the drug supply [of remdesivir], so there’s nothing for Europe,” said Dr Andrew Hill, senior visiting research fellow at Liverpool University.

Remdesivir, the first drug approved by licensing authorities in the US to treat Covid-19, is made by Gilead and has been shown to help people recover faster from the disease. 

The first 140,000 doses, supplied to drug trials around the world, have been used up. The Trump administration has now bought more than 500,000 doses, which is all of Gilead’s production for July and 90% of August and September.